miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression

被引:44
|
作者
Deng, Xin [1 ]
Zhao, Yi [1 ]
Wang, Baosheng [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Pancreat & Breast Surg, Shenyang 110004, Liaoning, Peoples R China
关键词
miR-519d; STAT3; breast cancer; metastasis; apoptosis; PROMOTES TUMOR-METASTASIS; EXPRESSION; MIR-519D; TARGETS; ROLES; PROLIFERATION; TRANSCRIPTION; MICRORNAS; PATHWAY;
D O I
10.3892/or.2015.4160
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) play important roles in the the gene regulation of carcinogenesis including breast cancer. miR-519d has been studied in various types of cancer, but its role in breast cancer remains unclear. In the present study, we investigated the expression and biological function of miR519d in breast cancer. Using quantitative RT-PCR (RT-qPCR) analysis, we analyzed the expression of miR-519d in breast cancer tissues and cell lines. It was shown that miR-519d expression was decreased in cancer tissues and cell lines compared with their controls. Overexpression of miR-519d inhibited cell proliferation and invasion, and induced apop.tosis of breast cancer cells. Signal transducer and activator of transcription 3 (STAT3) was predicted as a target gene of miR-519d and it was verified by the luciferase reporter assay. Additionally, STAT3 mRNA and protein expression levels were downregulated in the cells with miR-519d overexpression as determined by RT-qPCR and western blotting. Taken together, the results indicated that miR-519d functions as a tumor suppressor in breast cancer by suppressing STAT3 expression.
引用
收藏
页码:2188 / 2194
页数:7
相关论文
共 50 条
  • [41] miR-634 Decreases the Radioresistance of Human Breast Cancer Cells by Targeting STAT3
    Yang, Bilan
    Kuai, Feng
    Chen, Zhijun
    Fu, Deshun
    Liu, Jun
    Wu, Yiwei
    Zhong, Jun
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (03) : 241 - 248
  • [42] Tea polyphenol EGC suppresses colorectal cancer cell proliferation both in vitro and in vivo via downregulation of STAT3
    Luo, Ke-Wang
    Ye, Wei
    Li, Ning
    Cheng, Bao-Hui
    JOURNAL OF FUNCTIONAL FOODS, 2024, 112
  • [43] Role of STAT3 Phosphorylation in Ethanol-Mediated Proliferation of Breast Cancer Cells
    Narayanan, Poornima Devi
    Nandabalan, Sangeetha Kadapakkam
    Baddireddi, Lakshmi Subhadra
    JOURNAL OF BREAST CANCER, 2016, 19 (02) : 122 - 132
  • [44] Circulating miRNAs miR-519d and miR-150 associated with colon cancer progression
    Zhang, Mingxin
    Cui, Manli
    Wang, Jingjie
    Xi, Xiaohou
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 519 - 519
  • [45] ACSM3 Suppresses Ovarian Cancer Progression by Inactivating the IFN-γ/JAK/STAT3 Signaling Pathway
    Wang, Juan
    Sun, Yanqiu
    Wu, Ruixue
    ADVANCED BIOLOGY, 2025, 9 (03):
  • [46] Reciprocal Effects of STAT5 and STAT3 in Breast Cancer
    Walker, Sarah R.
    Nelson, Erik A.
    Zou, Lihua
    Chaudhury, Mousumi
    Signoretti, Sabina
    Richardson, Andrea
    Frank, David A.
    MOLECULAR CANCER RESEARCH, 2009, 7 (06) : 966 - 976
  • [47] Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway
    Changwei Qiu
    Tao Zhang
    Xinying Zhu
    Jinxia Qiu
    Kangfeng Jiang
    Gan Zhao
    Haichong Wu
    Ganzhen Deng
    Reproductive Sciences, 2019, 26 : 829 - 838
  • [48] Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway
    Qiu, Changwei
    Zhang, Tao
    Zhu, Xinying
    Qiu, Jinxia
    Jiang, Kangfeng
    Zhao, Gan
    Wu, Haichong
    Deng, Ganzhen
    REPRODUCTIVE SCIENCES, 2019, 26 (06) : 829 - 838
  • [49] Juzaowan Suppresses Glycolysis in Breast Cancer Cells by Inhibiting the STAT3/C-Myc Axis
    Zhou, Yuan
    Lin, Liumei
    Li, Fei
    Xu, Yuchun
    Peng, Huatong
    Chen, Qiang
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2025, 77 (01): : 149 - 163
  • [50] miR-29a inhibits human retinoblastoma progression by targeting STAT3
    Liu, Shu
    Zhang, Xiaomeng
    Hu, Chunmei
    Wang, Yingxue
    Xu, Chunling
    ONCOLOGY REPORTS, 2018, 39 (02) : 739 - 746